|
Variables
|
eGFR ≥ 90ml/min/1.73m2 (n = 1684)
|
eGFR 60–89 ml/min/1.73m2 (n = 719)
|
eGFR < 60ml/min/1.73m2 (n = 162)
|
p value
|
p* value
|
|---|
|
Male (n, %)
|
930 (55.2%)
|
410 (57.0%)
|
88 (54.3%)
|
0.674
|
< 0.001
|
|
Age (years)
|
56 ± 12
|
66 ± 10
|
69 ± 10
|
< 0.001
|
< 0.001
|
|
DD (months)*
|
72 (12–120)
|
96 (36–156)
|
120 (60–192)
|
< 0.001
|
0.234
|
|
Hypertension (n, %)
|
788 (46.8%)
|
456 (63.4%)
|
132 (81.5%)
|
< 0.001
|
< 0.001
|
|
Drinking (n, %)
|
287 (17.0%)
|
100 (13.9%)
|
10 (6.2%)
|
< 0.001
|
0.025
|
|
Smoking (n, %)
|
520 (30.9%)
|
185 (25.7%)
|
33 (20.4%)
|
0.002
|
0.358
|
|
APA (n, %)
|
789 (46.9%)
|
436 (60.6%)
|
92 (56.8%)
|
< 0.001
|
0.066
|
|
LLD (n, %)
|
509 (30.2%)
|
234 (32.5%)
|
56 (34.6%)
|
0.332
|
0.093
|
|
AHA (n, %)
|
700 (41.6%)
|
434 (60.4%)
|
126 (77.8%)
|
< 0.001
|
< 0.001
|
|
IIA (n, %)
|
1209 (71.8%)
|
491 (68.3%)
|
146 (90.1%)
|
< 0.001
|
< 0.001
|
|
Metformin (n, %)
|
993 (59.0%)
|
378 (52.6%)
|
73 (45.1%)
|
< 0.001
|
0.016
|
|
Insulin sensitizers (n,%)
|
258 (15.3%)
|
97 (13.5%)
|
22 (13.6%)
|
0.464
|
0.642
|
|
SBP (mmHg)
|
130 ± 17
|
134 ± 18
|
141 ± 21
|
< 0.001
|
< 0.001
|
|
DBP (mmHg)
|
80 ± 10
|
80 ± 10
|
80 ± 11
|
< 0.001
|
0.918
|
|
WC (cm)
|
88.62 ± 10.24
|
90.25 ± 10.32
|
92.51 ± 9.67
|
< 0.001
|
< 0.001
|
|
WHR
|
0.91 ± 0.06
|
0.91 ± 0.07
|
0.93 ± 0.06
|
< 0.001
|
0.009
|
|
BMI (kg/m2)
|
24.7 ± 3.48
|
25.13 ± 3.21
|
25.74 ± 3.69
|
< 0.001
|
< 0.001
|
|
FPG (mmol/l)*
|
8.07 (6.48–10.04)
|
7.27 (5.9-9)
|
7.06 (5.62–8.89)
|
< 0.001
|
< 0.001
|
|
2-h PPG (mmol/l)*
|
13.81 (10.51–17.17)
|
13.14 (9.66–16.49)
|
12.15
(9.58–16.94)
|
0.005
|
0.137
|
|
HbA1c (%)
|
9.34 ± 2.34
|
8.79 ± 2.29
|
8.81 ± 2.69
|
0.150
|
< 0.001
|
|
FCP (ng/mL)*
|
1.58 (0.94–2.33)
|
1.7 (1.1–2.53)
|
2.21 (1.2–3.58)
|
< 0.001
|
< 0.001
|
|
2-h PCP (ng/mL)*
|
3.46 (1.88–5.18)
|
4.12 (2.43–5.53)
|
4.18 (2.32–5.82)
|
< 0.001
|
< 0.001
|
|
HOMA2-IR*
|
1.4 (0.8-2)
|
1.4 (0.9–2.1)
|
2 (0.9–2.9)
|
0.050
|
< 0.001
|
|
TG (mmol/l)*
|
1.43 (0.99–2.14)
|
1.42 (1–2.03)
|
1.55 (1.08–2.39)
|
0.512
|
< 0.001
|
|
TC (mmol/l)
|
4.73 ± 1.1
|
4.67 ± 1.08
|
4.97 ± 1.45
|
< 0.001
|
0.001
|
|
HDL-C (mmol/l)
|
1.12 ± 0.3
|
1.11 ± 0.3
|
1.06 ± 0.3
|
< 0.001
|
< 0.001
|
|
LDL-C (mmol/l)
|
3.14 ± 0.95
|
3.07 ± 0.93
|
3.2 ± 1.08
|
< 0.001
|
0.251
|
|
ALT (U/l)*
|
20 (14–31)
|
19 (13–27)
|
16 (12–26)
|
0.006
|
0.607
|
|
SUA (µmol/l) *
|
292 (244–351)
|
330 (278–391)
|
414 (349–495)
|
< 0.001
|
< 0.001
|
- Values are expressed as the mean ± S.D, or median with interquartile range, or percentages
- eGFR estimated glomerular filtration rate, DD duration of diabetes, APA anti-platelet agents, LLD lipid-lowering drugs, AHA anti-hypertensive agents, IIA insulin or insulin analogue, SBP systolic blood pressure, DBP diastolic blood pressure, WC waist circumference, WHR waist-to-hip ratio, BMI body mass index, FPG fasting plasma glucose, 2-h PPG 2-h postprandial plasma glucose, HbA1c glycated hemoglobin A1c, FCP fasting C-peptide, 2-h PCP 2-h postprandial C-peptide, HOMA2-IR HOMA of insulin resistance, TG total triglycerides, TC total cholesterol, HDL-C high-density lipoprotein cholesterol, LDL-C low-density lipoprotein cholesterol, ALT alanine transaminase, SUA serum uric acid
- p value: The p-values were not adjusted for sex and age for the trend
- p* value: The p-values were adjusted for sex and age for the trend
- * The Kruskal-Wallis test was applied
